Treatment-specific risk of subsequent malignant neoplasms in five-year survivors of diffuse large B-cell lymphoma
Last Updated: Wednesday, March 13, 2024
Results from an analysis of the long-term risk of subsequent malignant neoplasms (SMNs) among 5-year DLBCL survivors show increased risks for survivors ≤40 years at first treatment and survivors treated with >4500 mg/m2 cyclophosphamide/>300 mg/m2 doxorubicin. Survivors who received rituximab had a lower risk of subdiaphragmatic solid SMNs (HR 0.5, 95% CI 0.3-1.0) compared with those who did not receive rituximab.
Advertisement
News & Literature Highlights
